Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec;205(6):2131-2133.
doi: 10.1111/bjh.19845. Epub 2024 Oct 19.

A new face in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia

Takeshi Kondo  1
Affiliations

A new face in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia

Takeshi Kondo. Br J Haematol. 2024 Dec.

Abstract

The prognosis for patients with relapsed/refractory or measurable (minimal) residual disease-positive Philadelphia chromosome (Ph)-positive acute lymphoblastic leukaemia (ALL) is poor. Currently, ponatinib is the only approved tyrosine kinase inhibitor (TKI) that is effective for Ph-positive ALL with the T315I mutation. Although the report by Liu et al. is a retrospective observational study, it offers prospects for the efficacy of chemotherapy combined with the novel third-generation TKI, olverembatinib, in these conditions, which may be validated in future prospective clinical trials. Commentary on: Liu et al. Efficacy and safety of olverembatinib in adult BCR::ABL1-positive ALL with T315I mutation or relapsed/refractory disease. Br J Haematol 2024; 205:2228-2233.

Keywords: Philadelphia chromosome (Ph)‐positive; acute lymphoblastic leukemia; minimal residual disease‐positive.

PubMed Disclaimer

References

REFERENCES

    1. Soverini S, De Benedittis C, Papayannidis C, Paolini S, Venturi C, Iacobucci I, et al. Drug resistance and BCR‐ABL kinase domain mutations in Philadelphia chromosome‐positive acute lymphoblastic leukemia from the imatinib to the second‐generation tyrosine kinase inhibitor era: the main changes are in the type of mutations, but not in the frequency of mutation involvement. Cancer. 2014;120(7):1002–1009.
    1. Sanford DS, Kantarjian H, O'Brien S, Jabbour E, Cortes J, Ravandi F. The role of ponatinib in Philadelphia chromosome‐positive acute lymphoblastic leukemia. Expert Rev Anticancer Ther. 2015;15(4):365–373.
    1. Senapati J, Sasaki K, Issa GC, Lipton JH, Radich JP, Jabbour E, et al. Management of chronic myeloid leukemia in 2023—common ground and common sense. Blood Cancer J. 2023;13(1):58.
    1. Jiang Q, Li Z, Qin Y, Li W, Xu N, Liu B, et al. Olverembatinib (HQP1351), a well‐tolerated and effective tyrosine kinase inhibitor for patients with T315I‐mutated chronic myeloid leukemia: results of an open‐label, multicenter phase 1/2 trial. J Hematol Oncol. 2022;15(1):113.
    1. Liu W, Wang C, Ouyang W, Hao J, Ren J, Peng L, et al. Efficacy and safety of olverembatinib in adult BCR::ABL1‐positive ALL with T315I mutation or relapsed/refractory disease. Br J Haematol. 2024 Online ahead of print. https://doi.org/10.1111/bjh.19804.

MeSH terms

LinkOut - more resources